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Libre de Bruxelles, CP160/12, Brussels, Belgium, 3 Malaria Public Health and Epidemiology Group, Centre for Geographic Medicine, KEMRI - University of Oxford Wellcome Trust Collaborative Programme, Nairobi, Kenya, 4 Department of Geography, University of Florida, Gainesville, Florida, United States of America, 5 Emerging
Pathogens Institute, University of Florida, Gainesville, Florida, United States of America, 6 Oxford University Clinical Research Unit, Bach Mai Hospital, National Institute of
Infectious and Tropical Diseases, Ha Noi, Vietnam, 7 Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia, 8 Centre for Tropical Medicine, Nuffield Department of
Clinical Medicine, Oxford University, Oxford, United Kingdom, 9 Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, CCVTM,
Oxford, United Kingdom

Abstract
Background: A research priority for Plasmodium vivax malaria is to improve our understanding of the spatial distribution of
risk and its relationship with the burden of P. vivax disease in human populations. The aim of the research outlined in this
article is to provide a contemporary evidence-based map of the global spatial extent of P. vivax malaria, together with
estimates of the human population at risk (PAR) of any level of transmission in 2009.
Methodology: The most recent P. vivax case-reporting data that could be obtained for all malaria endemic countries were
used to classify risk into three classes: malaria free, unstable (,0.1 case per 1,000 people per annum (p.a.)) and stable ($0.1
case per 1,000 p.a.) P. vivax malaria transmission. Risk areas were further constrained using temperature and aridity data
based upon their relationship with parasite and vector bionomics. Medical intelligence was used to refine the spatial extent
of risk in specific areas where transmission was reported to be absent (e.g., large urban areas and malaria-free islands). The
PAR under each level of transmission was then derived by combining the categorical risk map with a high resolution
population surface adjusted to 2009. The exclusion of large Duffy negative populations in Africa from the PAR totals was
achieved using independent modelling of the gene frequency of this genetic trait. It was estimated that 2.85 billion people
were exposed to some risk of P. vivax transmission in 2009, with 57.1% of them living in areas of unstable transmission. The
vast majority (2.59 billion, 91.0%) were located in Central and South East (CSE) Asia, whilst the remainder were located in
America (0.16 billion, 5.5%) and in the Africa+ region (0.10 billion, 3.5%). Despite evidence of ubiquitous risk of P. vivax
infection in Africa, the very high prevalence of Duffy negativity throughout Central and West Africa reduced the PAR
estimates substantially.
Conclusions: After more than a century of development and control, P. vivax remains more widely distributed than P.
falciparum and is a potential cause of morbidity and mortality amongst the 2.85 billion people living at risk of infection, the
majority of whom are in the tropical belt of CSE Asia. The probability of infection is reduced massively across Africa by the
frequency of the Duffy negative trait, but transmission does occur on the continent and is a concern for Duffy positive locals
and travellers. The final map provides the spatial limits on which the endemicity of P. vivax transmission can be mapped to
support future cartographic-based burden estimations.
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Author Summary

Methods

Growing evidence shows that Plasmodium vivax malaria is
clinically less benign than has been commonly believed. In
addition, it is the most widely distributed species of
human malaria and is likely to cause more illness in certain
regions than the more extensively studied P. falciparum
malaria. Understanding where P. vivax transmission exists
and measuring the number of people who live at risk of
infection is a fundamental first step to estimating the
global disease toll. The aim of this paper is to generate a
reliable map of the worldwide distribution of this parasite
and to provide an estimate of how many people are
exposed to probable infection. A geographical information
system was used to map data on the presence of P. vivax
infection and spatial information on climatic conditions
that impede transmission (low ambient temperature and
extremely arid environments) in order to delineate areas
where transmission was unlikely to take place. This map
was combined with population distribution data to
estimate how many people live in these areas and are,
therefore, exposed to risk of infection by P. vivax malaria.
The results show that 2.85 billion people were exposed to
some level of risk of transmission in 2009.

Analyses Outline
A schematic overview of the analyses is presented in Figure 1.
Briefly, P. vivax malaria endemic countries (PvMECs) were first
identified and the following layers were progressively applied
within a geographical information system to constrain risk areas
and derive the final P. vivax spatial limits map: i) a P. vivax annual
parasite incidence (PvAPI) data layer; biological exclusion layers
comprising of ii) temperature and iii) aridity data layers; iv) a
medical intelligence exclusion layer; and v) a predicted Duffy
negativity layer. A detailed description of these steps follows.

Identifying PvMECs
Those countries that currently support P. vivax transmission
were first identified. The primary sources for defining national risk
were international travel and health guidelines [25,26] augmented
with national survey information, pertinent published sources
and personal communication with malariologists. Nations were
grouped into three regions, as described elsewhere [19]: i)
America; ii) Africa, Saudi Arabia and Yemen (Africa+); and iii)
Central and South East (CSE) Asia. To further resolve PAR
estimates, the CSE Asia region was sub-divided into West Asia,
Central Asia and East Asia (Protocol S1).

Introduction
Mapping case-reporting data

The bulk of the global burden of human malaria is caused by
two parasites: Plasmodium falciparum and P. vivax. Existing research
efforts have focussed largely on P. falciparum because of the
mortality it causes in Africa [1,2]. This focus is increasingly
regarded as untenable [3–6] because the following factors indicate
that the public health importance of P. vivax may be more
significant than traditionally thought: i) P. vivax has a wider
geographical range, potentially exposing more people to risk of
infection [7,8]; ii) it is less amenable to control [9,10]; and, most
importantly, iii) infections with P. vivax can cause severe clinical
syndromes [5,11–16].
A key research priority for P. vivax malaria is to improve the
basic understanding of the geographical distribution of risk, which
is needed for adequate burden estimation [6]. Recent work by the
Malaria Atlas Project (MAP; www.map.ox.ac.uk) [17] has shown
P. falciparum malaria mapping to be a fundamental step in
understanding the epidemiology of the disease at the global scale
[18,19], in appraising the equity of global financing for control
[20] and in forming the basis for burden estimation [21,22]. The
benefits of a detailed knowledge of the spatial distribution of P.
vivax transmission, and its clinical burden within these limits, are
identical to those articulated for P. falciparum: establishing a
benchmark against which control targets may be set, budgeted and
monitored. Such maps do not exist for P. vivax, making any
strategic planning problematic. In addition, information about the
global extent of P. vivax transmission and population at risk (PAR)
is crucial for many nations that are re-evaluating their prospects
for malaria elimination [23,24].
This paper documents the global spatial limits of P. vivax
malaria using a combination of national case-reporting data from
health management information systems (HMIS), biological rules
of transmission exclusion and medical intelligence combined in a
geographical information system. The output is an evidencebased map from which estimates of PAR are derived. The
resulting map also provides the global template in which
contemporary P. vivax endemicity can be estimated and it
contributes to a cartographic basis for P. vivax disease burden
estimation.
www.plosntds.org

Methods described previously for mapping the global spatial
limits of P. falciparum malaria [18] were used to constrain the area
defined at risk within the PvMECs using PvAPI data (the number
of confirmed P. vivax malaria cases reported per administrative unit
per 1,000 people per annum (p.a.)). The PvAPI data were obtained
mostly through personal communication with individuals and
institutions linked to malaria control in each country (Protocol S1).
The format in which these data were available varied considerably
between countries. Ideally, the data would be available by
administrative unit and by year, with each record presenting the
estimated population for the administrative unit and the number
of confirmed autochthonous malaria cases by the two main
parasite species (P. falciparum and P. vivax). This would allow an
estimation of species-specific API. These requirements, however,
were often not met. Population data by administrative unit were
sometimes unavailable, in which cases these data were sourced
separately or extrapolated from previous years. An additional
problem was the lack of parasite species-specific case or API
values. In such cases, a parasite species ratio was inferred from
alternative sources and applied to provide an estimate of speciesspecific API. There was, thus, significant geographical variation in
the ability to look at the relative frequency of these parasites
between areas and this was not investigated further. Finally,
although a differentiation between confirmed and suspected cases
and between autochthonous and imported cases was often
provided, whenever this was not available it was assumed that
the cases in question referred to confirmed and autochthonous
occurrences.
The aim was to collate data for the last four years of reporting
(ideally up to 2009) at the highest spatial resolution available
(ideally at the second administrative level (ADMIN2) or higher). A
geo-database was constructed to archive this information and link
it to digital administrative boundaries of the world available from
the 2009 version of the Global Administrative Unit Layers
(GAUL) data set, implemented by the Food and Agriculture
Organization of the United Nations (FAO) within the EC FAO
Food Security for Action Programme [27]. The PvAPI data were
averaged over the period available and were used to classify areas
2
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Figure 1. Flow chart of the various data and exclusion layers used to derive the final map. The pink rectangle denotes the surface area
and populations of PvMECs, whilst the pink ovoid represents the resulting trimmed surface area and PAR after the exclusion of risk by the various
input layers, denoted by the blue rhomboids. Orange rectangles show area and PAR exclusions at each step to illustrate how these were reduced
progressively. The sequence in which the exclusion layers are applied does not affect the final PAR estimates.
doi:10.1371/journal.pntd.0000774.g001

as malaria free, unstable (,0.1 case per 1,000 p.a.) or stable ($0.1
case per 1,000 p.a.) transmission, based upon metrics advised
during the Global Malaria Eradication Programme [28–30].
These data categories were then mapped using ArcMAP 9.2
(ESRI 2006).

temperature and the duration of sporogony, based upon
parameters specific to P. vivax [31]. Synoptic mean, maximum
and minimum monthly temperature records were obtained from
30-arcsec (,161 km) spatial resolution climate surfaces [32]. For
each pixel, these values were converted, using spline interpolation,
to a continuous time series representing a mean temperature
profile across an average year. Diurnal variation was represented
by adding a sinusoidal component to the time series with a
wavelength of 24 hours and the amplitude varying smoothly
across the year determined by the difference between the monthly

Biological masks of exclusion of risk
To further constrain risk within national territories, two
‘‘masks’’ of biological exclusion were implemented (Protocol S2).
First, risk was constrained according to the relationship between
www.plosntds.org
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extents falling outside the range of the urban vector An. stephensi
[41] (Protocol S3) was excluded; ii) risk within urban areas
inhabited by An. stephensi was down-regulated by one level from
stable to unstable and from unstable to free (Protocol S3).
Specified sub-national territories were classified as malaria free if
not already identified as such by the PvAPI layer and the biological
masks. These territories were mapped using the GAUL data set
[27].

minimum and maximum values. For P. vivax transmission to be
biologically feasible, a cohort of anopheline vectors infected with
P. vivax must survive long enough for sporogony to complete
within their lifetime. Since the rate of parasite development within
anophelines is strongly dependent on ambient temperature, the
time required for sporogony varies continuously as temperatures
fluctuate across a year [31]. For each pixel, the annual
temperature profile was used to determine whether any periods
existed in the year when vector lifespan would exceed the time
required for sporogony, and hence when transmission was not
precluded by temperature. This was achieved via numerical
integration whereby, for cohorts of vectors born at each successive
2-hour interval across the year, sporogony rates varying
continuously as a function of temperature were used to identify
the earliest time at which sporogony could occur. If this time
exceeded the maximum feasible vector lifespan, then the cohort
was deemed unable to support transmission. If sporogony could
not complete for any cohort across the year, then the pixel was
classified as being at zero risk. Vector lifespan was defined as 31
days since estimates of the longevity of the main dominant vectors
[33] indicate that 99% of anophelines die in less than a month
and, therefore, would be unable to support parasite development
in the required time. The exceptions were areas that support the
longer-lived Anopheles sergentii and An. superpictus, where 62 days
were considered more appropriate (Protocol S2) [18].
The second mask was based on the effect of arid conditions on
anopheline development and survival [34]. Limited surface water
reduces the availability of sites suitable for oviposition and reduces
the survival of vectors at all stages of their development through
the process of desiccation [35]. The ability of adult vectors to
survive long enough to contribute to parasite transmission and of
pre-adult stages to ensure minimum population abundance is,
therefore, dependent on the levels of aridity and species-specific
resilience to arid conditions. Extremely arid areas were identified
using the global GlobCover Land Cover product (ESA/ESA
GlobCover Project, led by MEDIAS-France/POSTEL) [36].
GlobCover products are derived from data provided by the
Medium Resolution Imaging Spectrometer (MERIS), on board
the European Space Agency’s (ESA) ENVIronmental SATellite
(ENVISAT), for the period between December 2004 and June
2006, and are available at a spatial resolution of 300 meters [36].
The layer was first resampled to a 161 km grid using a majority
filter, and all pixels classified as ‘‘bare areas’’ by GlobCover were
overlaid onto the PvAPI surface. The aridity mask was treated
differently from the temperature mask to allow for the possibility
of the adaptation of human and vector populations to arid
environments [37–39]. A more conservative approach was taken,
which down-regulated risk by one class. In other words,
GlobCover’s bare areas defined originally as at stable risk by
PvAPI were stepped down to unstable risk and those classified
initially as unstable to malaria free.

Duffy negativity phenotype
Since Duffy negativity provides protection against infection with
P. vivax [42], a continuous map of the Duffy negativity phenotype
was generated from a geostatistical model fully described
elsewhere (Howes et al., manuscript in preparation). The model
was informed by a database of Duffy blood group surveys
assembled from thorough searches of the published literature and
supplemented with unpublished data by personal communication
with relevant authors. Sources retrieved were added to existing
Duffy blood group survey databases [43,44]. The earliest inclusion
date for surveys was 1950, when the Duffy blood group was first
described [45].
To model the Duffy system and derive a global prediction for
the frequency of the homozygous Duffy negative phenotype
([Fy(a-b-)], which is encoded by the homozygous FY*BES/*BES
genotype), the spatially variable frequencies of the two polymorphic loci determining Duffy phenotypes were modelled: i)
nucleotide 233 in the gene’s promoter region, which defines
positive/negative expression (T-33C); ii) the coding region locus
(G125A) determining the antigen type expressed: Fya or Fyb [46].
Due to the wide range of diagnostic methods used to describe
Duffy blood types in recent decades, data were recorded in a
variety of forms, each providing differing information about the
frequency of variants at both loci. For example, some molecular
studies sequenced only the gene’s promoter region, and thus could
not inform the frequency of the coding region variant; serological
diagnoses only testing for the Fya antigen could not distinguish Fyb
from the Duffy negative phenotype. As part of the larger dataset,
however, these incomplete data types can indirectly inform
frequencies of negativity. Therefore, despite only requiring
information about the promoter locus to model the negativity
phenotype, variant frequencies at both polymorphic sites were
modelled. This allowed the full range of information contained in
the dataset to be used rather than just the subset specifically
reporting Duffy negativity frequencies.
The model’s general architecture and Bayesian framework will
be described elsewhere (Howes et al., manuscript in preparation).
Briefly, the dataset of known values at fixed geographic locations
was used to predict expression frequencies at each locus in all
geographic sites where no data were available, thereby generating
continuous global surfaces of the frequency of each variant. From
the predicted frequency of the promoter region variant encoding
null expression (-33C), a continuous frequency map of the Duffy
negative population was derived.

Medical intelligence modulation of risk
Medical intelligence contained in international travel and health
guidelines [25,26] was used to inform risk exclusion and downregulation in specific urban areas and sub-national territories,
which are cited as being free of malaria transmission (Protocol S3).
Additional medical intelligence and personal communication with
malaria experts helped identify further sub-national areas classified
as malaria free in Cambodia, Vanuatu and Yemen. Specified
urban areas were geo-positioned and their urban extents were
identified using the Global Rural Urban Mapping Project
(GRUMP) urban extents layer [40]. Rules of risk modulation
within these urban extents were as follows: i) risk within urban
www.plosntds.org

Estimating the population at risk of P. vivax transmission
The GRUMP beta version provides gridded population counts
and population density estimates for the years 1990, 1995, and
2000, both adjusted and unadjusted to the United Nations’
national population estimates [40]. The adjusted population
counts for the year 2000 were projected to 2009 by applying
national, medium variant, urban and rural-specific growth rates by
country [47]. These projections were undertaken using methods
described previously [48], but refined with urban growth rates
being applied solely to populations residing within the GRUMP
4
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Kyrgyzstan and Uzbekistan, for which information contained in
the most recent travel and health guidelines [25,26] was used to
map risk. With the exception of Namibia, Saudi Arabia, South
Africa and Swaziland, which were treated like all other nations, no
HMIS data were solicited for countries in the Africa+ region,
where stable risk of P. vivax transmission was assumed to be present
throughout the country territories. In Botswana, stable risk was
assumed in northern areas as specified by travel and health
guidelines [25,26]. Amongst those countries for which HMIS data
were available, 16 reported at ADMIN1 and 29 at ADMIN2 level.
For Southern China, Myanmar, Nepal and Peru, data were
available at ADMIN3 level. Data for Namibia and Venezuela
were resolved at ADMIN1 and ADMIN2 levels. In total, 17,591
administrative units were populated with PvAPI data. Protocol S1
describes these data in detail. Figure 2 shows the spatial extent of
P. vivax transmission as defined by the PvAPI data, with areas
categorised as malaria free, unstable (PvAPI,0.1 case per 1,000
p.a.) or stable (PvAPI$0.1 case per 1,000 p.a.) transmission [29].

urban extents, while the rural growth rates were applied to the
remaining population. This resulted in a 2009 population count
surface of approximately 161 km spatial resolution, which was
used to extract PAR figures. The PAR estimates in Africa were
corrected for the presence of the Duffy negativity phenotype by
multiplying the extracted population by [1 - frequency of Duffy
negative individuals].

Results
Plasmodium vivax malaria endemic countries
A total of 109 potentially endemic countries and territories listed
in international travel and health guidelines were identified
[25,26]. Ten of these countries: Algeria, Armenia, Egypt, Jamaica
(P. falciparum only), Mauritius, Morocco, Oman, Russian Federation, Syrian Arab Republic and Turkmenistan have either
interrupted transmission or are extremely effective at dealing with
minor local outbreaks. These nations were not classified as
PvMECs and are all considered to be in the elimination phase by
the Global Malaria Action Plan [24]. Additionally, four malaria
endemic territories report P. falciparum transmission only: Cape
Verde [49], the Dominican Republic [50], Haiti [50,51] and
Mayotte [52]. This resulted in a global total of 95 PvMECs.
Figure 1 summarises the various layers applied on the 95 PvMECs
in order to derive the limits of P. vivax transmission. The results of
these different steps are described below.

Biological masks to refine the limits of transmission
Figure 3 shows the limits of P. vivax transmission after overlaying
the temperature mask on the PvAPI surface. The P. vivax-specific
temperature mask was less exclusive of areas of risk than that
derived for P. falciparum [18]. Exclusion of risk was mainly evident
in the Andes, the southern fringes of the Himalayas, the eastern
fringe of the Tibetan plateaux, the central mountain ridge of New
Guinea and the East African, Malagasy and Afghan highlands.
There was a remarkable correspondence between PvAPI defined
risk in the Andean and Himalayan regions and the temperature
mask, which trimmed pixels of no risk at very high spatial
resolution in these areas.
The aridity mask used here [36] was more contemporary and
derived from higher spatial resolution imagery than the one used
to define the limits of P. falciparum [18]. Figure 4 shows that the

Defining the spatial limits of P. vivax transmission at subnational level
PvAPI data were available for 51 countries. Data for four
countries were available up to 2009. For 29 countries the last year
of reporting was 2008, whilst 2007 and 2006 were the last years
available for 11 and six countries, respectively. For Colombia the
last reporting year was 2005. No HMIS data could be obtained for

Figure 2. Plasmodium vivax malaria risk defined by PvAPI data. Transmission was defined as stable (red areas, where PvAPI$0.1 per 1,000
people p.a.), unstable (pink areas, where PvAPI,0.1 per 1,000 p.a.) or no risk (grey areas). The boundaries of the 95 countries defined as P. vivax
endemic are shown.
doi:10.1371/journal.pntd.0000774.g002

www.plosntds.org
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Figure 3. Further refinement of Plasmodium vivax transmission risk areas using the temperature layer of exclusion. Risk areas are
defined as in Figure 2.
doi:10.1371/journal.pntd.0000774.g003

effects of the aridity mask were more evident in the Sahel and
southern Saharan regions, as well as the Arabian Peninsula. In the
western coast of Saudi Arabia, unstable risk defined by the PvAPI
layer was reduced to isolated foci of unstable risk by the aridity
mask. In Yemen, stable risk was constrained to the west coast and
to limited pockets along the southern coast. Similarly, endemic
areas of stable risk defined by PvAPI data in southern Afghanistan,

southern Iran and throughout Pakistan were largely reduced to
unstable risk by the aridity mask.

Medical intelligence used to refine risk
The two international travel and health guidelines consulted
[25,26] cite 59 specific urban areas in 31 countries as being
malaria free, in addition to urban areas in China, Indonesia (those

Figure 4. Aridity layer overlaid on the PvAPI and temperature layers. Risk areas are defined as in Figure 2.
doi:10.1371/journal.pntd.0000774.g004

www.plosntds.org
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Africa. For instance, the frequency of Duffy negativity in the South
African population was 62.7%, increasing to 65.0% in Namibia
and 73.5% across Madagascar. The situation was predicted to be
highly heterogeneous across Ethiopia, with an estimated 50.0% of
the overall population being Duffy negative.

found in Sumatra, Kalimantan, Nusa Tenggara Barat and
Sulawesi) and the Philippines (Protocol S3). A total of 42 of these
cities fell within areas classified as malarious and amongst these,
eight were found within the range of An. stephensi, as were some
urban areas in south-western Yunnan, China. Risk in the latter
was down-regulated from stable to unstable and from unstable to
free due to the presence of this urban vector. In the remaining 34
cities and other urban areas in China, Indonesia and the
Philippines, risk was excluded. In addition, 36 administrative
units, including islands, are cited as being malaria free (Protocol
S3). These territories were excluded as areas of risk, if not already
classified as such by the PvAPI surface and biological masks. In
addition, the island of Aneityum, in Vanuatu [53], the area around
Angkor Watt, in Cambodia, and the island of Socotra, in Yemen
[54], were classified as malaria free following additional medical
intelligence and personal communication with malaria experts
from these countries.

Populations at risk of P. vivax transmission
The estimated P. vivax endemic areas and PAR for 2009 are
presented in Table 1, stratified by unstable (PvAPI,0.1 per 1,000
p.a.) and stable (PvAPI$0.1 per 1,000 p.a.) risk of transmission,
globally and by region and sub-region. It was estimated that there
were 2.85 billion people at risk of P. vivax transmission worldwide
in 2009, the vast majority (91.0%) inhabiting the CSE Asia region,
5.5% living in America and 3.4% living in Africa+, after
accounting for Duffy negativity. An estimated 57.1% of the P.
vivax PAR in 2009 lived in areas of unstable transmission, with a
population of 1.63 billion.
Country level PAR estimates are provided in Protocol S4. The
ten countries with the highest estimated PAR, in descending order,
were: India, China, Indonesia, Pakistan, Viet Nam, Philippines,
Brazil, Myanmar, Thailand and Ethiopia. PAR estimates in India
accounted for 41.9% of the global PAR estimates, with 60.3% of
the more than one billion PAR (1.19 billion) living in stable
transmission areas. The situation in China was different as,
according to the PvAPI input data, areas of stable transmission
were only found in the southern provinces of Yunnan and Hainan,
and in the north-eastern province of Anhui, which reported an
unusually high number of cases up to 2007. The latter is in
accordance with a recent report documenting the resurgence of
malaria in this province [55]. Transmission in the rest of China
was largely negligible, with PvAPI values well below 0.1 case per
1,000 people p.a. Given the reported cases, however, these were
classified as unstable transmission areas and the total PAR
estimated within them, after urban exclusions, was 583 million

Frequency of Duffy negativity
From the assembled library of references, 821 spatially unique
Duffy blood type surveys were identified. Globally the data points
were spatially representative, with 265 in America, 213 in Africa+
(167 sub-Saharan), 207 in CSE Asia and 136 in Europe. The total
global sampled population was 131,187 individuals, with 24,816
(18.9%) in Africa+ and 33 African countries represented in the
final database.
The modelled global map of Duffy negativity (Figure 5)
indicates that the P. vivax resistant phenotype is rarely seen outside
of Africa, and, when this is the case, it is mainly in localised New
World migrant communities. Within Africa, the predicted
prevalence was strikingly high south of the Sahara. Across this
region, the silent Duffy allele was close to fixation in 31 countries
with 95% or more of the population being Duffy negative.
Frequencies fell sharply into southern Africa and into the Horn of

Figure 5. The global spatial limits of Plasmodium vivax malaria transmission in 2009. Risk areas are defined as in Figure 2. The medical
intelligence and predicted Duffy negativity layers are overlaid on the P. vivax limits of transmission as defined by the PvAPI data and biological mask
layers. Areas where Duffy negativity prevalence was estimated as $90% are hatched, indicating where PAR estimates were modulated most
significantly by the presence of this genetic trait.
doi:10.1371/journal.pntd.0000774.g005
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2007. It is important to stress the necessity to access PvAPI data at
a higher spatial resolution from China (i.e. at the county level) in
order to refine these estimates and minimise biases.

Table 1. Regional and global areas and PAR of Plasmodium
vivax malaria in 2009.

Region

Area (km2)
Unstable Stable

PAR (millions)
Any risk

Table 2. Published evidence of Plasmodium vivax malaria
transmission in African countries.

Unstable Stable Any risk

Africa+

4,812,618

17,980,708 22,793,326 20.1

77.9

98.0

America

1,368,380

8,087,335

9,455,715

58.8

157.8

CSE Asia

5,848,939

6,127,549

11,976,488 1,509.0

1,084.2 2,593.2

West Asia

99.0

Country

References*

2,007,247

2,800,612

4,807,859

653.9

845.2

1,499.2

Angola

[68–73]

Central Asia 3,156,574

1,277,219

4,433,793

694.3

129.2

823.4

Benin

[68,70,71,74]

East Asia

2,049,717

2,734,835

160.8

109.8

270.6

Botswana

[72]

Burkina Faso

[68,71]

Burundi

[70–73]

World

685,118

12,029,937 32,195,600 44,225,537 1,628.1

1,220.9 2,849.0

doi:10.1371/journal.pntd.0000774.t001

people. All other countries reporting the highest PAR were in CSE
Asia, with the exception of Brazil and Ethiopia.

Discussion
We present a contemporary evidence-based map of the global
distribution of P. vivax transmission developed from a combination
of mapped sub-national HMIS data, biological rules of transmission exclusion and medical intelligence. The methods used were
developed from those implemented for P. falciparum malaria [18]
and can be reproduced following the sequence of data layer
assemblies and exclusions illustrated in Figure 1.
Plasmodium vivax is transmitted within 95 countries in tropical,
sub-tropical and temperate regions, reaching approximately 43
degrees north in China and approximately 30 degrees south in
Southern Africa. The fact that P. vivax has a wider range than P.
falciparum [18] is facilitated by two aspects of the parasite’s biology
[56]: i) its development at lower temperatures during sporogony
[31]; and ii) its ability to produce hypnozoites during its life cycle
in the human host [57]. The sporogonic cycle of P. vivax is shorter
(i.e. a lower number of degree days required for its completion)
and the parasite’s sexual stage is active at lower temperatures than
other human malaria parasites (Protocol S2) [31]. Consequently,
generation of sporozoites is possible at higher altitudes and more
extreme latitudes. In the human host, hypnozoites of P. vivax
temperate strains can relapse anywhere between months and
years after the initial infection, often temporally coincident
with optimal climatic conditions in a new transmission season
[10,57].
The resulting maps produced an estimate of 2.85 billion people
living at risk of P. vivax malaria transmission in 2009. The
distribution of P. vivax PAR is very different from that of P.
falciparum [18], due to the widespread distribution of P. vivax in
Asia, up to northern China, and the high prevalence of the Duffy
negativity phenotype in Africa. China accounts for 22.0% of the
global estimated P. vivax PAR, although 93.1% of these people live
in areas defined as unstable transmission (Protocol S4). An
important caveat is that PvAPI data from central and northern
China could only be accessed at the lowest administrative level
(ADMIN1) (Protocol S1). The very high population densities
found in this country exacerbate the problem, inevitably biasing
PAR estimates, despite urban areas in China being excluded from
the calculations following information from the sources of medical
intelligence that were consulted [25,26]. Malaria transmission in
most of these unstable transmission areas in China is probably
negligible given the very few cases reported between 2003 and
www.plosntds.org

Cameroon

[68,69,71–79]

Cen. African Rep.

[68]

Chad

[74]

Comoros

[68]

Congo

[68,70,71,73,74,76,77,80]

Côte d’Ivoire

[68–71,73,74,76,78]

Congo (DR)

[68,81]

Djibouti

[68,78]

Equatorial Guinea

[82]

Eritrea

[71,73,76,77,83,84]

Ethiopia

[68–74,76–79,85]

Gabon

[68,71,86]

Gambia

[71,72,76,78]

Ghana

[69–74,76–79]

Guinea

[68,69,71,76,77]

Kenya

[68–73,76–79]

Liberia

[68–73,76–79]

Madagascar

[68–73,76,78,87]

Malawi

[68,70,72,73]

Mali

[68,69,71]

Mauritania

[68,69,71,72,76,77,88,89]

Mozambique

[68–71,73,76,79,90]

Namibia

[70]

Niger

[68,69,71,76]

Nigeria

[69–74,76–79,91]

Rwanda

[68,71,72,78]

São Tomé and Prı́ncipe

[68,92]

Senegal

[68,70,71,73,76,77]

Sierra Leone

[68,69,72–74,76,78]

Somalia

[69,70,78,79,93]

South Africa

[69–71,76–78]

Sudan

[68–74,76,77,79,94]

Togo

[70,71]

Uganda

[69–74,76–79,95]

Tanzania

[68–72,76,77,79]

Zambia

[69–72,78,96]

Zimbabwe

[68,69,71]

*The cited references mostly document imported cases from Africa. Evidence of
transmission of P. vivax in Guinea Bissau and Swaziland could not be found in
the published literature.
doi:10.1371/journal.pntd.0000774.t002
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In Africa, the modelled prevalence of Duffy negativity shows
that very high rates of this phenotype are present in large swaths of
West and Central Africa (Figure 5). One of the functions of the
Duffy antigen is being a receptor of P. vivax [46] and its absence
has been shown to preclude infection with this parasite [58,59],
although the extent of this has been questioned [60–63]. There is
no doubt that the African continent has a climate highly conducive
to P. vivax transmission (Protocol S2). Moreover, dominant African
Anopheles have been shown to be competent vectors of this parasite
[62,64,65]. In addition, there is a plethora of evidence of P. vivax
transmission in Africa, mostly arising from travel-acquired P. vivax
infections during visits to malaria endemic African countries
(Table 2; Protocol S1). This evidence supports the hypothesis that
P. vivax may have been often misdiagnosed as P. ovale in the region
due to a combination of morphological similarity and the
prevailing bio-geographical dogma driven by the high prevalence
of Duffy negativity [60]. Despite the fact that the risk of P. vivax is
cosmopolitan, PAR estimates in Africa were modulated according
to the high limitations placed on infection by the occurrence of the
Duffy negative trait. Consequently, the PAR in the Africa+ region
accounts for only 3.5% of the global estimated P. vivax PAR.
Although recent work has shown 42 P. vivax infections amongst
476 individuals genotyped as Duffy negative across eight sites in
Madagascar [63], we have taken a conservative approach and
consider it premature to relax the Duffy exclusion of PAR
across continental Africa until this study has been replicated
elsewhere.
Mapping the distribution of P. vivax malaria has presented a
number of unique challenges compared to P. falciparum, some of
which have been addressed by the methods used here. The
influence of climate on parasite development has been allowed for
by implementing a temperature mask parameterised specifically
for the P. vivax life cycle. The question of Duffy negativity and P.
vivax transmission has also been addressed by modelling the
distribution of this phenotype and by allowing the predicted
prevalence to modulate PAR. It is also worth noting that the
accuracy of HMIS for P. vivax clinical cases, particularly in areas of
coincidental P. falciparum risk, is notoriously poor [66], in part
because microscopists are less likely to record the presence of a
parasite assumed to be clinically less important. Here, HMIS data
were averaged over a period of up to four years and used to
differentiate malaria free areas from those that are malarious.
Within the latter, a conservative threshold was applied to classify
risk areas as being of unstable (PvAPI,0.1 per 1,000 p.a.) or stable
(PvAPI$0.1 per 1,000 p.a.) transmission [29]. We believe that this
conservative use of HMIS data balances, to some extent,
anomalies introduced by P. vivax underreporting and the
correspondence of the biological masks and PvAPI data in many
areas is reassuring.
The intensity of transmission within the defined stable limits of
P. vivax risk will vary across this range and this will be modelled
using geostatistical techniques similar to those developed recently
for P. falciparum [19]. This modelling work will be cognisant of the
unique epidemiology of P. vivax. First, in areas where P. vivax

infection is coincidental with P. falciparum, prevalence of the former
may be suppressed by cross-species immunity [67] or underestimated by poor diagnostics [66]. Second, there is the ability of P.
vivax to generate hypnozoites that lead to relapses. These
characteristics render the interpretation of prevalence measures
more problematic [5]. Third, the prevalence of Duffy negativity
provides protection against infection in large sections of the
population in Africa [58,59]. An appropriate modelling framework
is under development and will be the subject of a subsequent paper
mapping P. vivax malaria endemicity using parasite prevalence
data. These data are being collated in the MAP database, with
nearly 9,000 P. vivax parasite rate records archived by 01 March
2010.

Supporting Information
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Found at: doi:10.1371/journal.pntd.0000774.s001 (2.87 MB
DOC)
Protocol S2 Defining the global biological limits of Plasmodium

vivax transmission. Document describing more extensively two of
the layers used to create the final map.
Found at: doi:10.1371/journal.pntd.0000774.s002 (0.42 MB
DOC)
Protocol S3 Risk modulation based upon medical intelligence.
Document describing more extensively one of the layers used to
create the final map.
Found at: doi:10.1371/journal.pntd.0000774.s003 (0.36 MB
DOC)
Protocol S4 Country level area and population at risk of
Plasmodium vivax malaria in 2009. Country-level table of the
estimated area and populations at risk of P. vivax malaria in 2009
Found at: doi:10.1371/journal.pntd.0000774.s004 (0.16 MB
DOC)
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